Home » Topics » Cardiovascular, BioWorld Science

Cardiovascular, BioWorld Science
RSS

Theravance opens phase III study of TD-9855 to treat symptomatic neurogenic orthostatic hypotension

Jan. 11, 2019

Minnebro approved in Japan for hypertension

Jan. 8, 2019

Bristol-Myers Squibb patents formylpeptide FPR1 and FPR2 receptor agonists

Jan. 4, 2019

U.S. patients to join global phase II trial of mavrilimumab for giant cell arteritis

Jan. 3, 2019

New PDE9 inhibitors presented by Merck & Co.

Jan. 2, 2019

Bristol-Myers Squibb describes formyl peptide receptor agonists

Dec. 31, 2018

ROMK inhibitors reported in Bristol-Myers Squibb patent

Dec. 27, 2018

Otsuka opens enrollment in phase III trial of OPC-61815 for congestive heart failure

Dec. 27, 2018

Enanta Pharmaceuticals discloses MAP3K5 inhibitors

Dec. 20, 2018

Enanta Pharmaceuticals divulges MAP3K5 inhibitors

Dec. 19, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 20, 2026.
ALN-5288 lowers tau levels in preclinical models
BioWorld Science
Pathological tau accumulation is a key driver of neurodegeneration in Alzheimer’s disease (AD) and other tauopathies such as progressive supranuclear palsy....
Capital remains selective in ‘barbell’ biotech market
BioWorld
Signs of recovery are emerging in the biotechnology investment sector, although investors across Asia say that capital is flowing selectively to companies that...
Dual FAAH/MAGL inhibition targets Alzheimer’s disease hyperexcitability
BioWorld Science
Reduced endocannabinoid signaling has been linked to neuronal hyperexcitability in Alzheimer’s disease (AD), suggesting that dual inhibition of fatty acid amide...
LIT-002 is strong candidate for autism and neuropathic pain
BioWorld Science
Researchers from the University of Strasbourg and the Centre National de la Recherche Scientifique (CNRS) have presented data on LIT-002, a nonpeptide oxytocin...